• HD201, Trastuzumab 
  • HD204, Bevacizumab
  • PBP1502, Adalimumab
  • PBP1503, Biobetter, Bevacizumab
  • PBP1510, New antibody for pancreatic cancer treatment
  • PBP1505, Infliximab
  • PBP1506, Rituximab
  • PBP1507, Etanercept

PBP's R&D facilities located in the Biomedical Park of Singapore boast well-equipped multidisciplinary research infrastructure, supporting pharmaceutical R&D activities from discovery to nonclinical and clinical development.                             Read More

Visit here for updated news and resources.

Prestige BioPharma Pte Ltd

Prestige BioPharma focuses on discovery and development of innovative new biologics as well as biosimilars.

PBP's first biosimilar HD201, Trastuzumab, successfully completed Phase I clinical trial in EU in 2014 and currently under Phase III development.

PBP thrives to become one of the top biopharmaceuticals specializing in discovery of new biologics and next series of biosimilars.

"Creating Difference & Value for Human Health"

15 Tech Park Crescent Singapore Singapore 638117   Phone: +65.68639575    E-mail: info@prestigebiophrma.com

News & Resources

  • PBP brochure including technical information on HD201 and HD204 is available upone request. Please email us at info@prestigebiopharma.com  to request a copy.
  • PBP will be participating at the upcoming BIO2016, June 6-9, 2016, Moscone Center, San Francisco, California, USA.

Discovery and Development of New Biologics and Biosimilars

Prestige BioPharma

Our Pipeline